Learning Objectives
Upon completion of this education program the participant should be able to:

• Describe and differentiate between the typical and the less common clinical presentations of myeloma and other plasma cell disorders;
• Define and interpret the appropriate laboratory procedures, bone marrow findings and imaging studies necessary to evaluate and stage multiple myeloma and other plasma cell disorders;
• Describe and discuss the diagnostic criteria for multiple myeloma, smoldering myeloma (SMM) and monoclonal gammopathy of uncertain significance (MGUS);
• Distinguish between and apply the various staging systems for multiple myeloma;
• Describe and discuss the prognostic significance and treatment planning impact of cytogenetic changes in myeloma cells as detected by conventional cytogenetic karyotyping and by fluorescence in situ hybridization (FISH).

Target Audience
This learning activity is intended for medical oncologists, hematologists, stem cell transplant physicians, and other interested healthcare professionals who treat and manage myeloma and related diseases in the hematology/oncology and transplant patient settings.